New drug combo shows promise for Tough-to-Treat lymphoma

NCT ID NCT01838434

Completed Disease control Sponsor: Alliance for Clinical Trials in Oncology Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding idelalisib to lenalidomide helps people with mantle cell lymphoma that has returned or is resistant to treatment. Lenalidomide boosts the immune system to fight cancer, while idelalisib blocks enzymes that help cancer cells grow. The trial involved 106 participants and looked at safety and how long the cancer stayed under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: idelalisib and lenalidomide
What this could lead to: If it works, this combination could offer a new treatment option for people with mantle cell lymphoma that has come back or stopped responding to other therapies.
What could go wrong: This is an early-phase trial, so the benefits are not proven. The drugs may cause side effects, and the combination might not work better than lenalidomide alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

Contacts and locations

Locations

Ohio State University Medical Center

Columbus, Ohio, 43210, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
University of Chicago

Chicago, Illinois, 60637, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.